Astellas' gastric cancer therapy gets UK regulator's nod

Britain's health regulator said on Wednesday it has approved Japan-based Astellas Pharma's (4503.T), opens new tab therapy to treat a type of gastric cancer.

The monoclonal antibody, which can attach itself to certain cancer cells and destroy them, was approved in combination with a standard chemotherapy for adults with cancer in the stomach or the junction where the oesophagus joins the stomach.